Literature DB >> 25231462

Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma.

Derya Kivrak Salim1, Hasan Mutlu2, Melek Karakurt Eryilmaz2, Fatma Yalçin Musri2, Deniz Tural2, Hasan Şenol Coşkun2.   

Abstract

Autoimmune hepatitis is a rarely seen autoimmune paraneoplastic syndrome of thymic carcinoma. Chemotherapy may be an effective choice in the treatment of primary tumor and paraneoplastic disorder. In this case, we report a 32-year-old man presented with increased liver enzymes and cholestasis with a history of thymoma surgically removed four years ago. Liver biopsy showed chronic active autoimmune hepatitis. Computed tomography scan showed pulmonary metastases and pleural mass as a recurrence of thymic carcinoma, proven by biopsy. After four cycles of cisplatin plus adriamycin plus cyclophosphamide plus vincristine and six cycles of paclitaxel plus gemcitabine, maintenance metronomic cyclophosphamide plus etoposide regimen was offered to the patient. Complete biological signs of hepatitis without need for steroids or immune suppressors and complete radiologic response in primary tumor were achieved. Maintenance metronomic chemotherapy regimens may be an alternative to the current treatment options in patients with thymic carcinomas.
© The Author(s) 2014.

Entities:  

Keywords:  Metronomic therapy; maintenance therapy; paraneoplastic autoimmune hepatitis; thymic carcinoma

Mesh:

Year:  2014        PMID: 25231462     DOI: 10.1177/1078155214551318

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  2 in total

1.  Metronomics for thymic carcinoma.

Authors:  Jacobo Muñoz Del Toro; Patricia Cortez Castedo; Alfonso Cortés Salgado; M Eugenia Olmedo García; Pilar Garrido López
Journal:  Ecancermedicalscience       Date:  2014-12-18

2.  SS-A52 antigen expression in thymic carcinoma accompanied with Sjögren syndrome: A case report.

Authors:  Tomomi Isono; Tomoko Wakasa; Hidenori Kusumoto; Keiji Shimada; Takafumi Ogawa; Hiroyuki Shiono
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.